Teva Reaches Deal With Novo Nordisk Over Victoza Patent

Drug Industry Daily
A A
Teva Pharmaceuticals has agreed to a patent litigation settlement with Novo Nordisk that would see the generic drugmaker wait until December 2023 to begin marketing its generic version of the type 2 diabetes drug Victoza (liraglutide).

To View This Article:

Login

Subscribe To Drug Industry Daily